Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2006 1
2007 1
2008 1
2010 3
2011 2
2012 1
2014 1
2015 1
2018 3
2019 4
2020 1
2021 4
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Advanced Unclassified Renal Cell Carcinoma"
Page 1
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Lee CH, et al. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17. J Clin Oncol. 2022. PMID: 35298296 Free PMC article. Clinical Trial.
PURPOSE: To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non-clear-cell renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients had advanced non-clear-cell renal carcinoma …
PURPOSE: To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non-clear-cell rena …
Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Hes O. Trpkov K, et al. Mod Pathol. 2021 Jun;34(6):1167-1184. doi: 10.1038/s41379-021-00737-6. Epub 2021 Feb 1. Mod Pathol. 2021. PMID: 33526874 Free article.
Following these criteria, we propose as novel entities: eosinophilic solid and cystic renal cell carcinoma (ESC RCC), renal cell carcinoma with fibromyomatous stroma (RCC FMS) (formerly RCC with leiomyomatous or smooth muscle stroma), and …
Following these criteria, we propose as novel entities: eosinophilic solid and cystic renal cell carcinoma (ESC RCC), …
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB. McDermott DF, et al. J Clin Oncol. 2021 Mar 20;39(9):1029-1039. doi: 10.1200/JCO.20.02365. Epub 2021 Feb 2. J Clin Oncol. 2021. PMID: 33529058 Free PMC article. Clinical Trial.
PURPOSE: Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in patients with non-clear cell renal cell carcinoma (nccRCC). The phase II KEYNOTE-427 study (cohort B) was conducted to assess the efficacy and safety of sing …
PURPOSE: Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in patients with non-clear cell renal …
Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR, Acikgoz Y, Hasanov E. Wilson NR, et al. Int J Cancer. 2024 Mar 15;154(6):947-961. doi: 10.1002/ijc.34756. Epub 2023 Oct 12. Int J Cancer. 2024. PMID: 37823185 Review.
Non-clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. ...The nccRCC consists of a wide range of different histological subtypes, the maj …
Non-clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts y …
Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
Kwon R, Argani P, Epstein JI, Lombardo KA, Wang X, Pierorazio PM, Mehra R, Matoso A. Kwon R, et al. Am J Surg Pathol. 2021 Apr 1;45(4):450-462. doi: 10.1097/PAS.0000000000001629. Am J Surg Pathol. 2021. PMID: 33239504
Our recent study of early-onset unclassified eosinophilic renal cell carcinoma (RCC) demonstrated that two third of cases could be reclassified by performing a limited number of immunohistochemistry stains. ...Recognition of more-recently described RCC …
Our recent study of early-onset unclassified eosinophilic renal cell carcinoma (RCC) demonstrated that two third …
Renal cell carcinoma in children and adolescents: Single-center experience and literature review.
He M, Cai J, Zhu K, Gu W, Li M, Xiong J, Guan Z, Wang J, Shu Q. He M, et al. Medicine (Baltimore). 2021 Jan 15;100(2):e23717. doi: 10.1097/MD.0000000000023717. Medicine (Baltimore). 2021. PMID: 33466124 Free PMC article.
Renal cell carcinoma (RCC) is infrequent in the pediatric population. ...Two patients died after 4 and 17 months of follow-up, respectively.In conclusion, microphthalmia family translocation renal cell carcinoma is the predominant type of …
Renal cell carcinoma (RCC) is infrequent in the pediatric population. ...Two patients died after 4 and 17 months of fol …
Advanced Non-Clear Cell Kidney Cancer: In Search of Rational Treatment Approaches.
Ornstein MC, Hutson TE. Ornstein MC, et al. Cancer J. 2020 Sep/Oct;26(5):441-447. doi: 10.1097/PPO.0000000000000474. Cancer J. 2020. PMID: 32947312 Review.
Non-clear cell renal cell carcinoma (nccRCC) accounts for approximately 25% of RCC diagnoses. Although broadly labeled as "nccRCC," they comprised a host of histologies that include papillary, chromophobe, unclassified, and others. Moreover, the …
Non-clear cell renal cell carcinoma (nccRCC) accounts for approximately 25% of RCC diagnoses. Although broadly l …
Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation.
Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, Dalrymple NC, Chintapalli KN. Prasad SR, et al. Radiographics. 2006 Nov-Dec;26(6):1795-806; discussion 1806-10. doi: 10.1148/rg.266065010. Radiographics. 2006. PMID: 17102051 Review.
Renal cell carcinoma (RCC) is a cause of significant morbidity and mortality, with an estimated 35,000 new cases and 12,480 deaths in the United States in 2003. ...Collecting duct carcinoma and renal medullary carcinoma are associated wit …
Renal cell carcinoma (RCC) is a cause of significant morbidity and mortality, with an estimated 35,000 new cases and 12 …
Unclassified renal cell carcinoma: a report of 56 cases.
Lopez-Beltran A, Kirkali Z, Montironi R, Blanca A, Algaba F, Scarpelli M, Yorukoglu K, Hartmann A, Cheng L. Lopez-Beltran A, et al. BJU Int. 2012 Sep;110(6):786-93. doi: 10.1111/j.1464-410X.2012.10934.x. Epub 2012 Mar 8. BJU Int. 2012. PMID: 22404824
Our study of 56 cases of unclassified RCC describes the pathological features that can be applied to predict prognosis on a daily basis. In particular nuclear grade, TNM classification, tumour coagulative necrosis, tumour size, microvascular invasion and 2004 …
Our study of 56 cases of unclassified RCC describes the pathological features that can be applied to predict prognosis …
Oncological Outcomes of Patients with Non-Clear Cell Renal Cell Cancers: Subtypes of Unclassified and Translocation Renal Cell Cancers.
Gokalp F, Celik S, Sozen TS, Ozen AH, Aslan G, Izol V, Baltaci S, Muezzinoglu T, Akdogan B, Suer E, Tinay I. Gokalp F, et al. Urol J. 2022 Dec 25;20(1):29-33. doi: 10.22037/uj.v19i.7091. Urol J. 2022. PMID: 35892147 Free article.
PURPOSE: We aimed to compare oncological outcomes in the two rare subtypes, unclassified renal cell cancer (unRCC) and translocation RCC (tRCC), vs clear cell RCC (ccRCC). ...RESULTS: The overall (15.8%) and cancer-specific mortalities (11.1%) were fou …
PURPOSE: We aimed to compare oncological outcomes in the two rare subtypes, unclassified renal cell cancer (unRCC) and …
25 results